4
Changes in Ownership
Roivant Sciences Ltd. Filed Acc 0001140361-25-035890
President & Immunovant CEO sold 1,711,000 shares at an average $14.92 ($25,524,777)
- President & Immunovant CEO acquired 1,562,374 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Venker Eric President & Immunovant CEO | 2025-09-19 | Option exercise 10b5-1 | +1,000,000 | $3.85 | $3,850,000 | 2,653,585 | D |
| Venker Eric President & Immunovant CEO | 2025-09-19 | Sale 10b5-1 | −683,818 | $14.95 | $10,223,079 | 1,969,767 | D |
| Venker Eric President & Immunovant CEO | 2025-09-22 | Option exercise 10b5-1 | +462,374 | $3.85 | $1,780,140 | 2,432,141 | D |
| Venker Eric President & Immunovant CEO | 2025-09-22 | Option exercise 10b5-1 | +100,000 | $3.85 | $385,000 | 2,532,141 | D |
| Venker Eric President & Immunovant CEO | 2025-09-22 | Sale 10b5-1 | −316,182 | $14.99 | $4,739,568 | 2,215,959 | D |
| Venker Eric President & Immunovant CEO | 2025-09-22 | Sale 10b5-1 | −100,000 | $15.01 | $1,501,000 | 2,115,959 | D |
| Venker Eric President & Immunovant CEO | 2025-09-23 | Sale 10b5-1 | −611,000 | $14.83 | $9,061,130 | 1,504,959 | D |
| Derivatives | |||||||
| Venker Eric President & Immunovant CEO | 2025-09-19 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,000,000 | 7,038,897 | D | ||
| Venker Eric President & Immunovant CEO | 2025-09-22 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −462,374 | 6,576,523 | D | ||
| Venker Eric President & Immunovant CEO | 2025-09-22 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −100,000 | 6,476,523 | D | ||
| Open-market sales · 1,711,000 sh · avg $14.92 · $25,524,777 | |||||||
Loading xslF345X05/form4.xml…